On May 12, the US Food and Drug Administration (FDA) granted approval to oral edaravone (RADICAVA ORS) for the treatment of ALS/MND. This antioxidant drug was approved in 2017 but required IV administration. The long-term safety and tolerability of RADICAVA ORS up to 96 weeks is currently being evaluated in an ongoing phase 3 study. Although not available in New Zealand, it is hoped this drug may be considered by Medsafe as more studies show the impact it has on people with MND/ALS. Click here to read more about this drug.
